High Ionized Calcium in the General Population and Risk of Primary Hyperparathyroidism - Top-Institutions - MDSpire

High Ionized Calcium in the General Population and Risk of Primary Hyperparathyroidism

  • By

  • Camilla J Kobylecki

  • Børge G Nordestgaard

  • Shoaib Afzal

  • February 20, 2025

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Endocrinology
    • Metabolic Bone Disease
    • Clinical Research

  • #2

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Endocrinology
    • Clinical Epidemiology
    • Metabolic Bone Disease

  • #3

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Endocrinology
    • Bone and Mineral Metabolism
    • Clinical Research

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Endocrinology
    • Metabolic Bone Disease
    • Population Health

  • #5

    Copenhagen University Hospital (Rigshospitalet)
    Copenhagen University Hospital (Rigshospitalet)

    Copenhagen, Denmark

    Key Differentiators

    • Endocrinology
    • Clinical Epidemiology
    • Metabolic Bone Disease

Original Source(s)

High Ionized Calcium in the General Population and Risk of Primary Hyperparathyroidism

  • by Camilla J Kobylecki, Børge G Nordestgaard, Shoaib Afzal

  • February 20, 2025

Related Content

Mortality and causes of death after surgery for chronic subdural hematoma: a post hoc study of the FINISH randomized trial

Prediction model for depression risk in middle-aged and elderly patients with metabolic syndrome: a nomogram and interpretable machine learning approach based on CHARLS

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.